NCLT order on merger of Shilpa Therapeutics Private Limited a wholly owned subsidiary with Shilpa Media Limited
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NCLT Bengaluru Bench has approved the scheme to merge Shilpa Therapeutics Private Limited, a wholly owned subsidiary, into Shilpa Medicare Limited, with an appointed date of 1 April 2025. Since Shilpa Therapeutics is fully owned by Shilpa Medicare, no new shares will be issued and the subsidiary's shares will simply be cancelled. The scheme will become effective only after certified copies of the NCLT order are filed with the Registrar of Companies. The transferor company is loss-making while the parent is profit-making, and the merger is largely a simplification of the group structure. All regulatory authorities including Income Tax, RBI and ROC have given their consent or no-objection, with various undertakings from the company on tax, MSME dues and FEMA compliance.
No material impact on shareholders — since this is a wholly owned subsidiary merging into the listed parent, no new shares are issued, no swap ratio applies, and there is no change in the capital structure of Shilpa Medicare. The stock price is unlikely to move meaningfully on this news; it is a routine internal restructuring.